Unknown statusInterventionalPhase 2Last updated Dec 13, 2022

Beta-glucans for Hospitalised Patients With COVID-19

Beta-glucans as Immune Modulators Amongst Hospitalised Patients With COVID-19: A Pilot Randomised Trial

Overview

ClinicalTrials.gov ID: NCT05465798
Lead Sponsor: Wohlstand PharmaceuticalINDUSTRY
Brief Summary: This randomised trial aims to assess the role of beta1-3 glucan supplementation in improving clinical symptoms and other outcomes amongst hospitalised patients with COVID-19.
Study Type: Interventional

Status

Study Record Dates

NCT03769012Completed

Ability of Beta-glucan Supplementation to Augment Immune Function

NCT03117439Completed

Beta-Glucan Driven vs. Empirical Antifungal Therapy in Critically Ill Patients

NCT01727895Completed

Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans

NCT06545149Not yet recruiting

SUPPLEMENTATION WITH BETA GLUCAN AND ADAPTATIVE RESPONSE.

NCT05878834Unknown status

Efficacy and Safety of Beta-glucan Supplement in Chronic Obstructive Pulmonary Disease Patients

NCT05074303Completed

Beta-glucan and Immune Response to Influenza Vaccine